- Home
- FGI vs CERO Comparison
FGI vs CERO Comparison
Compare FGI & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- CERO
- Stock Information
- Founded
- FGI 1987
- CERO 2017
- Country
- FGI United States
- CERO United States
- Employees
- FGI N/A
- CERO N/A
- Industry
- FGI Industrial Specialties
- CERO
- Sector
- FGI Industrials
- CERO
- Exchange
- FGI Nasdaq
- CERO Nasdaq
- Market Cap
- FGI 5.5M
- CERO 3.5M
- IPO Year
- FGI 2022
- CERO N/A
- Fundamental
- Price
- FGI $0.85
- CERO $8.70
- Analyst Decision
- FGI
- CERO Strong Buy
- Analyst Count
- FGI 0
- CERO 2
- Target Price
- FGI N/A
- CERO $45.00
- AVG Volume (30 Days)
- FGI 172.3K
- CERO 3.3M
- Earning Date
- FGI 08-06-2025
- CERO 08-13-2025
- Dividend Yield
- FGI N/A
- CERO N/A
- EPS Growth
- FGI N/A
- CERO N/A
- EPS
- FGI N/A
- CERO N/A
- Revenue
- FGI $134,277,102.00
- CERO N/A
- Revenue This Year
- FGI $7.72
- CERO N/A
- Revenue Next Year
- FGI $6.94
- CERO N/A
- P/E Ratio
- FGI N/A
- CERO N/A
- Revenue Growth
- FGI 11.13
- CERO N/A
- 52 Week Low
- FGI $0.46
- CERO $6.71
- 52 Week High
- FGI $1.20
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- FGI 65.65
- CERO 46.62
- Support Level
- FGI $0.64
- CERO $9.10
- Resistance Level
- FGI $0.87
- CERO $9.73
- Average True Range (ATR)
- FGI 0.09
- CERO 1.50
- MACD
- FGI 0.02
- CERO -0.01
- Stochastic Oscillator
- FGI 93.52
- CERO 10.78
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.